FOX CHASE CANCER CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1904-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.foxchase.org
A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults
Not Applicable
Completed
- Conditions
- Skin Neoplasms
- Interventions
- Behavioral: UV4meBehavioral: Skin Cancer Foundation website
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 1234
- Registration Number
- NCT02147080
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Comparative Effectiveness of CTC & OC
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 244
- Registration Number
- NCT02143115
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation
Completed
- Conditions
- Signet Ring Adenocarcinoma of the RectumStage IIC Rectal CancerStage IIIA Rectal CancerRecurrent Rectal CancerStage IIIB Rectal CancerStage IIB Rectal CancerMucinous Adenocarcinoma of the RectumStage IIA Rectal CancerStage IIIC Rectal Cancer
- Interventions
- Other: cytology specimen collection procedureOther: laboratory biomarker analysis
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT02132858
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer
Not Applicable
Completed
- Conditions
- Malignant Neoplasm
- Interventions
- Other: cytology specimen collection procedureDrug: targeted therapyProcedure: therapeutic procedureOther: laboratory biomarker analysis
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT02132845
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Not Applicable
Terminated
- Conditions
- Malignant Pericardial EffusionMalignant Pleural EffusionRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- Procedure: therapeutic procedureOther: cytology specimen collection procedureOther: laboratory biomarker analysisDrug: targeted therapy
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02132884
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Facilitating Participation in a Prostate Cancer Risk Assessment Program
Not Applicable
Completed
- Conditions
- Prostate Cancer
- Interventions
- Behavioral: Cognitive Affective preparationBehavioral: General Health Education
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT02126319
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
Phase 1
Terminated
- Conditions
- Stage IVA Rectal CancerMucinous Adenocarcinoma of the ColonRecurrent Colon CancerStage IVB Colon CancerRecurrent Rectal CancerSignet Ring Adenocarcinoma of the ColonSignet Ring Adenocarcinoma of the RectumStage IVA Colon CancerLiver MetastasesMucinous Adenocarcinoma of the Rectum
- Interventions
- Combination Product: irinotecan-eluting beadsProcedure: hepatic artery embolization
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT02110953
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
- Conditions
- Neuroendocrine Tumor
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT02092714
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Not Applicable
Completed
- Conditions
- Recurrent Adult Primary Liver CancerStage D Adult Primary Liver Cancer (BCLC)Unspecified Adult Solid Tumor, Protocol SpecificAdult Primary Hepatocellular CarcinomaRecurrent Extrahepatic Bile Duct CancerAdvanced Adult Primary Liver CancerMetastatic Extrahepatic Bile Duct Cancer
- Interventions
- Procedure: PET scanProcedure: CT ScanProcedure: hepatic artery embolization
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02088775
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1
Withdrawn
- Conditions
- Recurrent Fallopian Tube CancerOvarian Papillary Serous CarcinomaOvarian Serous CystadenocarcinomaRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT02050009
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath